Parliamentary Search

Written question asked by Toby Perkins (Labour) on Monday, 9 March 2026, in the House of Commons. It was due for an answer on Wednesday, 11 March 2026. It was answered by Zubir Ahmed (Labour) on Wednesday, 18 March 2026 on behalf of the Department of Health and Social Care.

Fampridine

Question

To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on access to fampridine for people with multiple sclerosis in England.

Answer

Health is a devolved matter and decisions on the availability of medicines in the devolved administrations are a matter for their own governments.

Ministers and Department officials have had no recent discussions with the National Institute for Health and Care Excellence (NICE) about access to fampridine. NICE’s updated guideline on the diagnosis and management of multiple sclerosis (MS) in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with MS as it is not found to be a cost-effective treatment at the current list price. NICE keeps its guidance under active surveillance and decisions on whether published guidelines should be updated in light of new evidence are taken by the NICE prioritisation board, chaired by the NICE Chief Medical Officer, in line with its published prioritisation framework. NICE has indicated that it has no current plans to review its recommendations on fampridine.

Secondary information

Type
Written question
Reference
118727
Session
2024-26
Grouped for answer
Yes
Subjects
Fampridine
Link
View this Written question on www.parliament.uk